{"id":"metformin-plus-vildagliptin","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Hypoglycemia"},{"rate":"5-10","effect":"Nasopharyngitis"},{"rate":"<0.1","effect":"Lactic acidosis (rare, metformin-related)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination targets type 2 diabetes through complementary pathways: metformin acts as a biguanide that decreases liver glucose output and enhances peripheral insulin sensitivity, while vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs the action of endogenous GLP-1 and GIP, thereby stimulating glucose-dependent insulin secretion and suppressing glucagon. Together, they provide synergistic glycemic control with different mechanisms of action.","oneSentence":"Metformin reduces hepatic glucose production and improves insulin sensitivity, while vildagliptin inhibits DPP-4 to increase incretin-mediated insulin secretion and reduce glucagon.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:42.781Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06851962","phase":"PHASE4","title":"Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2025-05-26","conditions":"Diabetes Mellitus Type 2","enrollment":504},{"nctId":"NCT04300790","phase":"PHASE2","title":"Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients","status":"COMPLETED","sponsor":"MedSIR","startDate":"2020-10-23","conditions":"Breast Cancer","enrollment":69},{"nctId":"NCT07077525","phase":"PHASE4","title":"Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2023-06-01","conditions":"Type 2 Diabetes","enrollment":196},{"nctId":"NCT04841096","phase":"PHASE3","title":"Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2023-03-21","conditions":"Type 2 Diabetes","enrollment":162},{"nctId":"NCT06068686","phase":"NA","title":"Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2022-10-01","conditions":"Type 2 Diabetes","enrollment":70},{"nctId":"NCT04017221","phase":"","title":"Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":"Diabetes Mellitus, Type 2, Urosepsis, Diabetic Ketoacidosis","enrollment":1249636},{"nctId":"NCT06570980","phase":"","title":"Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-08-25","conditions":"Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin","enrollment":200},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT03918148","phase":"","title":"Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2018-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":1150},{"nctId":"NCT05369793","phase":"PHASE3","title":"Clinical Study Evaluating the Safety and Efficacy of Roflumilast in Type 2 Diabetic Patients With Diabetic Neuropathy","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-08-01","conditions":"Type 2 Diabetes (Adult Onset), Diabetic Neuropathies","enrollment":60},{"nctId":"NCT05366868","phase":"PHASE4","title":"Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"National Center for Global Health and Medicine, Japan","startDate":"2022-05-26","conditions":"Diabetes Mellitus, Type 2","enrollment":567},{"nctId":"NCT06010992","phase":"PHASE2","title":"Nitazoxanide as Adjuvant Therapy in Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-10-01","conditions":"Diabetes Mellitus, Type 2","enrollment":70},{"nctId":"NCT05902468","phase":"PHASE2, PHASE3","title":"Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-06-28","conditions":"Diabetes Mellitus, Type 2","enrollment":88},{"nctId":"NCT03693560","phase":"PHASE4","title":"Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2018-10-08","conditions":"Coronary Artery Disease, Diabetes Mellitus, Type 2","enrollment":80},{"nctId":"NCT02244164","phase":"NA","title":"Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.","status":"TERMINATED","sponsor":"Erasme University Hospital","startDate":"2014-10","conditions":"Type 2 Diabetes, Incretinomimetics, Pancreas","enrollment":5},{"nctId":"NCT05347459","phase":"","title":"Cognitive Protective Effect of Newer Antidiabetic Drugs","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-03-02","conditions":"Type 2 Diabetes","enrollment":100},{"nctId":"NCT05429554","phase":"","title":"The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients","status":"UNKNOWN","sponsor":"MTI University","startDate":"2022-06","conditions":"Type 2 Diabetes Mellitus","enrollment":60},{"nctId":"NCT05337969","phase":"NA","title":"The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Assessed.","status":"COMPLETED","sponsor":"AET Laboratories Private Limited","startDate":"2015-12","conditions":"To Determine Bioequivalence Under Fed Conditions","enrollment":60},{"nctId":"NCT05329857","phase":"NA","title":"The Study Intends to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Evaluated.","status":"COMPLETED","sponsor":"AET Laboratories Private Limited","startDate":"2015-12","conditions":"To Determine Bioequivalence Under Fed Conditions","enrollment":60},{"nctId":"NCT03958591","phase":"PHASE4","title":"Effects of Short-term Intensive De-escalation Therapy on Long-term Regimen Simplification","status":"UNKNOWN","sponsor":"Yanbing Li","startDate":"2019-05-01","conditions":"Diabetes type2","enrollment":274},{"nctId":"NCT05041673","phase":"NA","title":"Anti-diabetic Drugs and Fatty Liver Management","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2021-02-23","conditions":"Fatty Liver, Nonalcoholic, Diabetes Mellitus, Type 2","enrollment":120},{"nctId":"NCT04916093","phase":"PHASE4","title":"Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2019-12-20","conditions":"Diabetes Mellitus, Type 2","enrollment":60},{"nctId":"NCT00860288","phase":"PHASE2, PHASE3","title":"Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2","enrollment":1988},{"nctId":"NCT00382096","phase":"PHASE3","title":"Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-09","conditions":"Diabetes Mellitus, Type 2","enrollment":1179},{"nctId":"NCT04654676","phase":"PHASE4","title":"DPP4 Inhibitor on Glycemic Variability","status":"COMPLETED","sponsor":"University Malaysia Sarawak","startDate":"2018-09-15","conditions":"Diabetes Mellitus, Type 2","enrollment":12},{"nctId":"NCT00728351","phase":"PHASE3","title":"Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-06","conditions":"Diabetes Mellitus, Type 2","enrollment":317},{"nctId":"NCT00468039","phase":"PHASE3","title":"A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-03-06","conditions":"Diabetes Mellitus, Type 2","enrollment":94},{"nctId":"NCT00383578","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-09","conditions":"Diabetes Mellitus, Type 2","enrollment":335},{"nctId":"NCT00396357","phase":"PHASE3","title":"Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-10","conditions":"Diabetes Mellitus, Type 2","enrollment":914},{"nctId":"NCT00106340","phase":"PHASE3","title":"Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-03","conditions":"Diabetes Mellitus, Type 2","enrollment":3118},{"nctId":"NCT00102466","phase":"PHASE3","title":"Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-01","conditions":"Diabetes Mellitus, Type 2","enrollment":1007},{"nctId":"NCT01528254","phase":"PHASE4","title":"VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03-30","conditions":"Type 2 Diabetes Mellitus","enrollment":2004},{"nctId":"NCT04485845","phase":"PHASE4","title":"Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2019-11-01","conditions":"Metabolic Syndrome, Diabete Type 2, Kidney Insufficiency","enrollment":39},{"nctId":"NCT04237493","phase":"PHASE4","title":"Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan","status":"COMPLETED","sponsor":"University of Jordan","startDate":"2017-02-14","conditions":"Diabetes Mellitus, Type 2","enrollment":687},{"nctId":"NCT03577184","phase":"","title":"Evaluating the Glycemic Control wIth Vildagliptin and Metformin Combination Therapy.","status":"WITHDRAWN","sponsor":"Clinision","startDate":"2018-07","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT03983551","phase":"PHASE4","title":"Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas","status":"COMPLETED","sponsor":"Changhua Christian Hospital","startDate":"2016-03-01","conditions":"Type 2 Diabetes Mellitus, Proteinuria","enrollment":101},{"nctId":"NCT02475070","phase":"PHASE4","title":"Vildagliptin Versus Dapagliflozin on Glucagon","status":"COMPLETED","sponsor":"Lund University","startDate":"2016-01","conditions":"Type 2 Diabetes","enrollment":28},{"nctId":"NCT03925701","phase":"PHASE3","title":"Clinical Study Evaluating Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM","status":"RECRUITING","sponsor":"Sherief Abd-Elsalam","startDate":"2019-04-01","conditions":"dm","enrollment":120},{"nctId":"NCT02853630","phase":"PHASE4","title":"A Clinical Trial to Study the Effects of Two Drugs, Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals","startDate":"2013-12","conditions":"TYpe 2 Diabetes Mellitus","enrollment":203},{"nctId":"NCT01882907","phase":"PHASE4","title":"Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes","status":"COMPLETED","sponsor":"Pusan National University Hospital","startDate":"2009-12","conditions":"Type 2 Diabetes","enrollment":287},{"nctId":"NCT03819127","phase":"PHASE4","title":"Vildagliptin in Older Adults With Diabetes and Mild Cognitive Impairment","status":"COMPLETED","sponsor":"University of Catania","startDate":"2015-01","conditions":"Mild Cognitive Impairment","enrollment":60},{"nctId":"NCT01404676","phase":"PHASE4","title":"The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2010-06","conditions":"Type 2 Diabetes Mellitus","enrollment":34},{"nctId":"NCT03253562","phase":"PHASE4","title":"Metformin Versus Vildagliptin for Diabetic Hypertensive Patients","status":"COMPLETED","sponsor":"MTI University","startDate":"2017-02-01","conditions":"Reducing the Elevated Blood Pressure for Diabetic Hypertensive Patients","enrollment":120},{"nctId":"NCT00099892","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-05","conditions":"Diabetes Mellitus, Type 2","enrollment":544},{"nctId":"NCT01822548","phase":"PHASE3","title":"Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria di Parma","startDate":"2010-10","conditions":"Type 2 Diabetes","enrollment":64},{"nctId":"NCT01196546","phase":"PHASE4","title":"Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-03","conditions":"Type 2 Diabetes Mellitus","enrollment":161},{"nctId":"NCT02007278","phase":"PHASE4","title":"Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-01-03","conditions":"Type 2 Diabetes, Hypoglycemia","enrollment":40},{"nctId":"NCT01766778","phase":"PHASE4","title":"Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-05-13","conditions":"Type-2 Diabetes Mellitus","enrollment":117},{"nctId":"NCT03088670","phase":"PHASE3","title":"Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.","status":"COMPLETED","sponsor":"SatRx LLC","startDate":"2013-04-23","conditions":"Diabetes Mellitus, Type 2","enrollment":299},{"nctId":"NCT00138515","phase":"PHASE3","title":"Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-11","conditions":"Diabetes Mellitus, Type 2","enrollment":418},{"nctId":"NCT00494884","phase":"PHASE3","title":"Vildagliptin 100 mg Once Daily vs. Placebo as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-06","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT01518101","phase":"PHASE4","title":"Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-01","conditions":"Type 2 Diabetes","enrollment":62},{"nctId":"NCT01497522","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-12","conditions":"Diabetes Mellitus, Type 2","enrollment":183},{"nctId":"NCT01426802","phase":"PHASE4","title":"Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-10","conditions":"Type 2 Diabetes Mellitus","enrollment":150},{"nctId":"NCT01224366","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-09","conditions":"Type 2 Diabetes Mellitus","enrollment":448},{"nctId":"NCT01233622","phase":"PHASE3","title":"Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-10","conditions":"Type 2 Diabetes Mellitus","enrollment":317},{"nctId":"NCT01238978","phase":"PHASE4","title":"Phase 4 Study in the Elderly Patients With T2DM","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-10","conditions":"Type 2 Diabetes Mellitus, Elderly","enrollment":46},{"nctId":"NCT00237237","phase":"PHASE3","title":"Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-10","conditions":"Diabetes Mellitus, Type 2","enrollment":588},{"nctId":"NCT00822211","phase":"PHASE3","title":"Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-12","conditions":"Type 2 Diabetes Mellitus","enrollment":404},{"nctId":"NCT00396227","phase":"PHASE3","title":"Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-10","conditions":"Diabetes Mellitus, Type 2","enrollment":2665},{"nctId":"NCT00138567","phase":"PHASE3","title":"Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-01","conditions":"Diabetes Mellitus, Type 2","enrollment":530},{"nctId":"NCT01541956","phase":"PHASE4","title":"Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-02","conditions":"Type 2 Diabetes","enrollment":3091},{"nctId":"NCT00396071","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin Compared to Placebo on the Incretin Effect in Patients With Type 2 Diabetes Treated With Metformin","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-10","conditions":"Diabetes Mellitus, Type 2","enrollment":22},{"nctId":"NCT00351884","phase":"PHASE3","title":"Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-05","conditions":"Diabetes Mellitus, Type 2","enrollment":370},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT01582243","phase":"PHASE4","title":"Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-04","conditions":"Diabetes Mellitus, Type 2","enrollment":40},{"nctId":"NCT01472432","phase":"PHASE4","title":"DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2011-05","conditions":"Chronic Foot Ulcers","enrollment":106},{"nctId":"NCT02145611","phase":"PHASE4","title":"Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension","status":"COMPLETED","sponsor":"Dr. José Fernando Vilela-Martin MD PhD","startDate":"2013-07","conditions":"Type 2 Diabetes Mellitus, Hypertension, Endothelial Dysfunction","enrollment":50},{"nctId":"NCT02343926","phase":"PHASE3","title":"Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-12","conditions":"Type 2 Diabetes Mellitus","enrollment":443},{"nctId":"NCT02749032","phase":"PHASE1","title":"Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) Secretion","status":"COMPLETED","sponsor":"Michael A. Nauck","startDate":"2011-11","conditions":"Type 2 Diabetes","enrollment":24},{"nctId":"NCT01871558","phase":"PHASE3","title":"Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-06","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":42},{"nctId":"NCT02142309","phase":"PHASE4","title":"Glycemic Durability After Metformin Failure","status":"UNKNOWN","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2005-10","conditions":"Type 2 Diabetes","enrollment":450},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT01604213","phase":"PHASE4","title":"Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2012-09","conditions":"Type 2 Diabetes Mellitus, Ischemic Heart Disease","enrollment":60},{"nctId":"NCT02368704","phase":"","title":"Role of Endoplasmic Reticulum Stress in the Pathophysiology of Type 2 Diabetes","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-11","conditions":"Diabetes Mellitus, Type 2, Endoplasmic Reticulum Stress","enrollment":40},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":886172},{"nctId":"NCT02002221","phase":"PHASE4","title":"Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":156},{"nctId":"NCT01922492","phase":"NA","title":"Effect of Islet Autotransplantation Compared to Oral Antidiabetic Drug.","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2008-05","conditions":"Partial Pancreatectomy Due to Benign Pancreatic Neoplasm","enrollment":28},{"nctId":"NCT01910441","phase":"PHASE4","title":"Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-07","conditions":"Type 2 Diabetes Mellitus","enrollment":95},{"nctId":"NCT01759823","phase":"PHASE2, PHASE3","title":"Bone Marrow Derived Stem Cell Transplantation in T2DM","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2012-12","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT01065298","phase":"","title":"Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus-2","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2009-11","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT01757587","phase":"PHASE4","title":"Galvus (Vildagliptin) vs Placebo in Combination With Metformin and Insulin","status":"COMPLETED","sponsor":"Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète","startDate":"2011-12","conditions":"Type 2 Diabetes","enrollment":39},{"nctId":"NCT01811485","phase":"PHASE3","title":"Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-05","conditions":"Diabetes Mellitus, Type 2","enrollment":171},{"nctId":"NCT01099137","phase":"PHASE4","title":"Effect of Vildagliptin in Type 2 Diabetes Treated With Sulphonylurea and Metformin","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2010-01","conditions":"Diabetes","enrollment":344},{"nctId":"NCT01867502","phase":"PHASE4","title":"Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2014-04","conditions":"Diabetes Mellitus, Type 2, Hypoglycemic Agents, Diabetic Blood Glucose Monitoring","enrollment":20},{"nctId":"NCT01758380","phase":"PHASE4","title":"Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-01","conditions":"Type 2 Diabetes Mellitus","enrollment":557},{"nctId":"NCT01963130","phase":"","title":"Does Vildagliptin Affect Portal Vein Pressure In Patients With Type 2 Diabetes Mellitus? A Cross Sectional Study","status":"COMPLETED","sponsor":"Bezmialem Vakif University","startDate":"2012-07","conditions":"Drug Mechanism, Drug Usage","enrollment":97},{"nctId":"NCT01356381","phase":"PHASE4","title":"Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-04","conditions":"Type 2 Diabetes Mellitus","enrollment":43},{"nctId":"NCT01582230","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-04","conditions":"Type 2 Diabetes Mellitus","enrollment":293},{"nctId":"NCT00975065","phase":"PHASE4","title":"Galvus on Met Phase 4 Study : Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2009-08","conditions":"Type 2 Diabetes Mellitus","enrollment":266},{"nctId":"NCT00099866","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-01","conditions":"Diabetes Mellitus, Type 2","enrollment":570},{"nctId":"NCT01193296","phase":"PHASE4","title":"Glycemic Holter Study (Continuous Glucose Monitoring) -","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-06","conditions":"Type 2 Diabetes Mellitus","enrollment":36},{"nctId":"NCT01565096","phase":"PHASE4","title":"Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy","status":"UNKNOWN","sponsor":"ikfe-CRO GmbH","startDate":"2011-11","conditions":"Diabetes Mellitus Type II","enrollment":44},{"nctId":"NCT01426737","phase":"PHASE4","title":"The Swiss Glucose Variability Study","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2011-04","conditions":"Type 2 Diabetes","enrollment":50},{"nctId":"NCT01339143","phase":"PHASE4","title":"Compare the Effect of DPP-IV Inhibitor or TZD on Glycemic Variability and Oxidative Stress in Patient With 2 Diabetes","status":"UNKNOWN","sponsor":"Korea University Anam Hospital","startDate":"2010-04","conditions":"Diabetes Mellitus, Oxidative Stress","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":57,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Eucreas"],"phase":"marketed","status":"active","brandName":"Metformin plus vildagliptin","genericName":"Metformin plus vildagliptin","companyName":"Sheba Medical Center","companyId":"sheba-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin reduces hepatic glucose production and improves insulin sensitivity, while vildagliptin inhibits DPP-4 to increase incretin-mediated insulin secretion and reduce glucagon. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2007-11-14T00:00:00.000Z","mah":"Novartis Europharm Limited","brand_name_local":"Eucreas","application_number":"EMEA/H/C/000807"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}